Alternative Splicing of IGF1 Gene as a Potential Factor in the Pathogenesis of Peyronie's Disease.

BACKGROUND/AIM: Peyronie's disease (PD) is a fibrotic entity for which the pathogenetic mechanism remains unclear and if resulting in severe deformity, its treatment is only surgical. In this study we investigated the possible role of insulin-like growth factor 1 (IGF1) expression in the pathogenesis of PD. MATERIALS AND METHODS: Tissue samples were obtained from plaques of 24 patients with PD. The expression of IGF1 isoforms was investigated using quantitative real-time polymerase chain reaction and immunofluorescence. RESULTS: All IGF1 isoform gene expression (Ea, Eb and Ec) were found significantly decreased in the affected tunica albuginea, compared to normal tunica albuginea, with Ec showing the greatest decrease. Staining of tissue sections with an antibody against IGF1Ec confirmed greater expression of IGF1Ec isoform in normal tunica albuginea. CONCLUSION: The expression of all IGF1 alternative spliced isoforms is decreased in patients with PD, suggestive of its possible participation in the pathophysiology of PD.

US Imaging in Peyronie's Disease.

The aim of this study is to assess the role of ultrasound (US) in Peyronie's Disease (PD). PD is a psychologically and physically devastating disorder that manifests in middle-aged men. Fibrous inelastic plaques in the tunica albuginea, result in palpable penile scar in the flaccid condition and cause painful erections and penile deformity, including penile curvature, hinging, narrowing, and shortening of penis. Penile deformity is the most common (52%) first symptom of PD and is present in 94% of affected men. US is the primary imaging modality of choice due to its easy availability, low risk, and ability to image and quantify both calcified and soft tissue elements of PD. US provides identification of smaller and non-palpable lesions and shows the extent of fibrosis. Detection of calcifications within the plaque suggests stabilization of the disease and provides information useful to select patients for appropriate treatment.

Comparison between lidocaine and glyceryl trinitrate ointment for perianal-intrarectal local anesthesia before transrectal ultrasonography-guided prostate biopsy: a placebo-controlled trial.

OBJECTIVE: To evaluate the use of topical lidocaine gel and glyceryl trinitrate ointment (GTN) vs placebo, in reducing anal pain and discomfort as an adjunct to periprostatic anesthesia because of probe insertion, during the use of transrectal ultrasonography (TRUS) prostate-guided biopsy in young patients. PATIENTS AND METHODS: Two-hundred twenty-three men who underwent prostate biopsy were divided into 3 groups. Seventy-four patients (first group) and 76 patients (second group) received perianal local anesthesia with lidocaine gel 2%, and 1 g of 0.4% GTN ointment, respectively, whereas 73 patients (third group) received lubricant gel as perianal local anesthesia. All patients also underwent periprostatic nerve block (PPNB). Visual analogue scales (VAS 1 and VAS 2) were used to estimate the pain and discomfort during probe insertion and biopsy. RESULTS: Men in the first and second groups reported significantly less pain score (mean, 1.7 and 1.6, respectively) vs men from the third group (mean, 5.7) during probe insertion. Comparing the 3 different groups subsequently with the periprostatic anesthesia, no significant difference in VAS scores between the first and the third groups (mean, 1.9 and 2.1, respectively) was found; in addition, patients from the second group reported significantly less pain score (mean, 1.3) during biopsy. CONCLUSIONS: Lidocaine gel and GTN ointment is safe and effective in reducing anal pain associated with the insertion of an ultrasound probe. Furthermore, men with GTN ointment also reported less pain during biopsy. We suggest that analgesia before PPNB could significantly reduce anal pain and improve tolerance during TRUS prostate-guided biopsy.

Post-fertilization effects of chronic renal failure in male rats.

We evaluated the potential for growth and intrauterine development of embryos generated from the fertilization of oocytes with spermatozoa recovered from animals with chronic renal failure (CRF). Group A included sham-operated rats (n = 28), group B1 involved CRF rats that had undergone erythropoietin plus bromocryptine treatment (n = 28), and group B2 included CRF rats that had received normal saline. Embryos derived from the in vitro fertilization of oocytes with spermatozoa recovered from rats of group A or group B1 or group B2 were transferred to female recipients. We induced CRF in a group of rats (group B; n = 56; the total kidney volume was reduced to one-sixth with two operations). One week after the second operation, the rats of group B were randomly divided into group B1 (they subsequently received bromocryptine plus erythropoietin) and group B2 (they received injections of saline). Nine weeks after the second operation, the fertility of each male rat was assessed by mating tests and in vitro fertilization of oocytes. The mean litter size was significantly smaller in the subpopulation of fertile animals in group B2 than in the fertile rats of group B1 and in the fertile rats of group B1 than in the fertile rats of group A. Per cent of transferred blastocysts that developed into alive offspring were significantly lower in group B2 than in group B1 and in group B1 than in group A. Epididymal spermatozoa demonstrated a significantly larger DNA-oxidative damage in group B2 than in group B1 and in group B1 than in group A. These findings demonstrate that sperm-DNA damage because of CRF development is accompanied by a defect in the development of embryos generated in vitro. We may suggest that bromocryptine and erythropoietin protecting sperm DNA from oxidative damage improve reproductive potential in rats with CRF.

Penile Mondor's disease: a case report.

INTRODUCTION: Thrombosis or thromboflebitis of the superficial dorsal vein of the penis, known as penile Mondor's disease was first described by Braun-Falco in 1955. CASE PRESENTATION: A physically healthy 32-year-old man proceed in our unit suffered from a painful swelling, on the dorsal aspect of his penis, being more painful during erections. Ultrasonography examination revealed a non-compressible portion of superficial dorsal vein as well as the lack of venous flow signals in Doppler ultrasonography and the patient was treated conservatively. CONCLUSION: Penile Mondor's disease is a rare clinical entity that every urologist should be able to recognize. Although it is a benign condition and usually self-limited, patients proceed to specialist with considerable psychological stress.

An overview of stress urinary incontinence treatment in women.

Stress urinary incontinence (SUI) is common in women, but it is under-reported and under-treated. We review here the management of SUI in women. Pelvic floor muscle training treats SUI in the majority of female patients, whereas anti-SUI devices are not widely accepted. Duloxetine has been approved for treating SUI. Suburethral slings have revolutionized the surgical management of SUI with durable efficacy, in contrast with injectable bulking agents.

Where are we with the treatment of metastatic bladder cancer?

Although bladder cancer is a chemosensitive tumor, metastatic disease is related with poor prognosis and short-term survival. For two decades, the treatment of choice for metastatic bladder cancer has been cisplatin-based chemotherapy. Nowadays, non-platinum regimes have been tested such as taxanes and gemcitabine, which is considered as an attractive alternative. In parallel, double and triplet combination chemotherapy have been assessed in clinical trials. Furthermore, individualized treatments through the identification of molecular prognostic factors and application of targeted therapy have gained considerable interest.

Leydig cell tumor of the testis. New cases and review of the current literature.

Leydig cell tumors are the most frequent non-germ cell tumors of the testis, accounting for 1-3% of all testicular tumors. They present most commonly as a testicular mass or with endocrine symptoms. We report three new cases of Leydig cell tumors that presented in different forms. The relevant literature is reviewed and the management of these tumors is discussed.